Clinical Impact of a Highly Sensitive Next-Generation Sequencing Measurable Residual Disease Assay in Patients with Acute Lymphoblastic Leukemia

....................................................................................................iii Table of contents..........................................................................................iv List of illustrations.........................................................................................v List of tables...............................................................................................v

[1]  V. Sundaram,et al.  Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. , 2021, Blood advances.

[2]  E. Jabbour,et al.  Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms , 2021, Leukemia.

[3]  G. Chatterjee,et al.  A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients , 2020, Cytometry. Part B, Clinical cytometry.

[4]  M. Konopleva,et al.  The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival , 2019, American journal of hematology.

[5]  A. Logan,et al.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.

[6]  M. Konopleva,et al.  Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage , 2018, Cancer.

[7]  H. Dombret,et al.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.

[8]  M. Loh,et al.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. , 2018, Blood.

[9]  D. Berry,et al.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.

[10]  M. Trková,et al.  Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. , 2017, Blood.

[11]  E. Froňková,et al.  Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL , 2017, Bone Marrow Transplantation.

[12]  Quentin Lecrevisse,et al.  Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.

[13]  M. Konopleva,et al.  Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia , 2017, Cancer.

[14]  A. Vitale,et al.  Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL) , 2016 .

[15]  R. Pieters,et al.  Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[17]  M. Konopleva,et al.  Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. , 2016, Blood.

[18]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[19]  L. Medeiros,et al.  T-lymphoblastic leukemia/lymphoma. , 2015, American journal of clinical pathology.

[20]  M. Loh,et al.  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.

[21]  E. Mejstrikova,et al.  The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. , 2015, Blood.

[22]  C. Desmarais,et al.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. , 2015, Blood.

[23]  J. Bourhis,et al.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.

[24]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[25]  R. Emerson,et al.  Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.

[26]  R. Wade,et al.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. , 2013, The Lancet. Oncology.

[27]  D. Campana,et al.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. , 2012, Blood.

[28]  E. Thiel,et al.  Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. , 2012, Blood.

[29]  S. Richards,et al.  Minimal residual disease is a significant predictor of treatment failure in non T‐lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 , 2010, British journal of haematology.

[30]  B. Wood,et al.  9-color and 10-color flow cytometry in the clinical laboratory. , 2006, Archives of pathology & laboratory medicine.

[31]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[32]  J. Dongen,et al.  TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse , 2004, Leukemia.